SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. - Wikidata - wikimedia - TriplyDB

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

http://www.wikidata.org/entity/Q44720331

about

Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Targeting tumor-stromal interactions in bone metastasis Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations.Phase II open-label study of sunitinib in patients with advanced breast cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis.An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.M-CSF mediates TNF-induced inflammatory osteolysis Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.Triple-negative breast cancer.A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors Musculoskeletal molecular imaging: a comprehensive overview.Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases Renal cell carcinoma bone metastases: clinical advances Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.

P2860

Q24810598-FDD7C6F7-B119-43BC-BA41-6A8D8922B879 Q26826817-CBA84E10-229B-4616-B7F0-EA1DE5940D40 Q27024561-A2B01694-892C-479F-9215-B44BF1AF4603 Q27851455-DEE4E952-23D7-4433-95CC-1A4C3DE38E4E Q27851744-004784DE-4070-4B16-82D9-EB0961682278 Q28247449-FE15DC08-CA02-4184-972D-4F82977332EA Q30422736-01A30799-5004-4D44-8CBF-2E4811A6EF0F Q31037756-51DC084A-BD96-46B1-8117-F64E8410C23A Q31137466-D91E4426-EB7B-4D8B-9FE5-718BB42FCBD4 Q33397590-B45C2505-CB26-42F2-9040-DB28F839D639 Q33400952-4CB6DAA7-4AF8-4684-901B-49FB2273BC8A Q33401396-943AA6E9-1F9D-40BA-8AB0-E1D04342F4C2 Q33403257-01816280-13A5-474A-B607-04605261E714 Q33403848-4BDE17E2-F62B-4E16-A6A0-5937BA3E9E21 Q33409913-EEB21B8D-A089-48C0-8C9B-BBC456F2C509 Q33411581-F19EC1FC-7139-46A7-AF30-A75C629EE8BE Q33565239-7ECCA2C4-98BE-4243-BB7D-40DAB385C8A3 Q33613666-A7CD4FAA-CB5E-4128-99F6-8B4D3B781A11 Q33648995-1E5F11EE-6EAA-44CB-BFBF-C2E3D15371E2 Q33723668-4A636875-BCBE-426E-BA5E-91613AD2C3EE Q33726477-A9181B7A-3B3D-4DDD-A23F-003E617D7E25 Q33902070-1B2255D4-D330-4A0C-BAF7-C436248BB7E0 Q33932531-E4DF3B36-61E9-4DCF-BCD5-049BB97C0154 Q33996608-6C7B0282-A59E-4CEB-842D-CFD65AA8B074 Q34111200-ED4B84A0-5621-479B-A77E-7AB73A36274E Q34115782-5336CB62-ABE0-4094-920E-3CE87B499434 Q34133595-CEA2F81E-FD19-46BA-BD60-538DF4B8722B Q34246117-00F71475-84D6-466C-BEBB-E4CC57E5F419 Q34248681-54AA2F64-65C7-4434-9418-2B8AB85ADB9E Q34250125-ABDE0C80-2A46-4126-83DF-9A6FAAA127BB Q34274939-6D4FD482-5A97-4272-BB5E-CC52B3444BFA Q34334959-33B254E9-E350-4182-9B5D-FA7FE85A7861 Q34473019-031BFE75-EE81-4644-8E86-3E9E5F968EF9 Q34561406-F4254047-D757-4C1D-9E6E-4B7876C2359D Q34631216-FB47E7BC-A71B-4DB9-9576-2E010E62BA59 Q34656707-271A10A1-5280-4BC7-8459-91731E63A712 Q34884647-0454A842-B0CC-43A6-8990-BFF53B8497FA Q35001643-29353ED9-20DB-489F-B297-AD0A79D1546A Q35114038-0AC1B778-59BC-471B-AC14-6A7F2CBB57A8 Q35184195-DF0CEFF1-1975-4DF5-BDD2-CDD5FD1C0B16

P2860

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

http://www.wikidata.org/entity/Q44720331

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@en

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@nl

type

label

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@en

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@nl

prefLabel

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@en

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@nl

P1433

Q44720331-B5F92249-688E-4106-A041-1D3D141DFCBA

P1476

Q44720331-37B3080D-5242-43B2-858B-2E86BBA84B92

P2093

Q44720331-19A523DC-0B97-424B-AF97-8E1C97E29380

Q44720331-3A800E97-64E8-4A00-9429-32B0C3737593

Q44720331-3F30FFB3-7D05-466B-884C-DF9AA5BC93F5

Q44720331-44392034-4162-44DC-A506-F9B2C6B276C7

Q44720331-698EA753-94EC-452D-8EE8-9FD9E58B2D32

Q44720331-6C33890E-7A90-49E5-9DFF-1747B691BF43

Q44720331-9672535F-4FB6-4CDB-9637-C17F54886375

Q44720331-C6AC0A7E-7C8C-415C-A1DF-8CEF60A8961E

Q44720331-D3B20F2C-7A82-4C63-9598-DA519EA1CE1D

Q44720331-F68F33E5-CAD1-4E1E-A961-370B7DB71727

P2888

Q44720331-9321A8BC-33A3-4279-B546-FDCD15CF13D4

P304

Q44720331-231E65D2-72C6-4382-810E-2187EF6961B7

P31

Q44720331-200D6792-4D2E-4C4E-8D83-6E2084BEE03D

P356

Q44720331-E4BA9720-C23C-47EA-9800-EA831C7E5753

P433

Q44720331-321ADE59-F56E-43E8-97CE-4F6E4945C404

P478

Q44720331-7258F400-466F-4E64-B1E2-775F1DDF9B88

P577

Q44720331-99A3C2EC-E938-474B-8FAB-82DB200B6709

P6179

Q44720331-87B327C1-D205-4FB5-9B43-D8A0D227C33A

P698

Q44720331-5583A2EE-9CED-4A74-98DD-6C68C77D7754

P356

B:CLIN.0000006873.65590.68

P1433

Clinical & Experimental Metastasis

P1476

SU11248 inhibits tumor growth ...... cancer bone metastasis model.

@en

P2093

Anne Marie O'Farrell

http://www.w3.org/2001/XMLSchema#string

Jacqueline A Brassard

http://www.w3.org/2001/XMLSchema#string

Julie M Cherrington

http://www.w3.org/2001/XMLSchema#string

Kelly R Long

http://www.w3.org/2001/XMLSchema#string

Lesley J Murray

http://www.w3.org/2001/XMLSchema#string

Lisa M Olson

http://www.w3.org/2001/XMLSchema#string

Nancy K Pryer

http://www.w3.org/2001/XMLSchema#string

Paul K Keast

http://www.w3.org/2001/XMLSchema#string

Theresa J Ngai

http://www.w3.org/2001/XMLSchema#string

Tinya J Abrams

http://www.w3.org/2001/XMLSchema#string

P2888

b:clin.0000006873.65590.68

P304

757-766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/B:CLIN.0000006873.65590.68

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020033628

http://www.w3.org/2001/XMLSchema#string

P698

14713109

http://www.w3.org/2001/XMLSchema#string